Perrigo announced that pharmaceutical company Esteve Healthcare has signed a binding offer to acquire Perrigo’s HRA Pharma Rare Diseases business for a total consideration of up to EUR 275M, consisting of an upfront cash payment of EUR 190M and up to EUR 85M in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by Esteve and enter into a definitive agreement with Esteve for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRGO:
- Perrigo price target raised to $39 from $35 at Piper Sandler
- CVS to cover Perrigo birth control drug at no cost, Bloomberg reports
- Perrigo recent pullback a buying opportunity, says Argus
- 5 Stocks Corporate Insiders are Buying in March 2024
- Erica Mann Retires from Perrigo Board After Influential Tenure